Intermediate and long-term outcomes of a low-cost non-valved glaucoma drainage device in refractory glaucoma

Session Details

Session Title: Microinvasive Glaucoma Surgery

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 15:00

Venue: Free Paper Forum: Podium 4

First Author: : F.Thattaruthody INDIA

Co Author(s): :    S. Pandav   N. Seth   A. Jurangal   S. Kaushik   S. Raj                 

Abstract Details

Purpose:

To study intermediate, long-term efficacy and safety of low-cost non-valved glaucoma drainage implant {Aurolab Aqueous Drainage Implant (AADI)} in refractory glaucomas in North Indian population.

Setting:

Tertiary Eye Care

Methods:

Retrospective consecutive review of patients more than > 18 years, who underwent AADI surgery between Jan 2013 to Dec 2018, who had at least 6 months documented follow-up. The primary outcome measured was Intraocular Pressure (IOP). The number of anti-glaucoma medications (AGM), logMAR Best Corrected Visual Acuity (BCVA) and complications were measures as secondary outcomes. The postoperative visual acuity, IOP and complications were analyzed at day 1, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4years and 5 years along with AGM. Additional procedures on follow up visit were documented.

Results:

Two seventy-two eyes of 264 patients (186 female and 78 males) were included with a mean age of 47.01±17.34 years and mean follow-up was 23.33± 17.33 months. The mean preoperative IOP and AGM were 29.86 mm Hg and 4.58 respectively, were significantly reduced all follow up visit (P<0.001). Early, intermediate and long term complications occurred in 55.55%, 14.7%, and 10.2% respectively. The mean BCAV was remained unchanged (p>0.05). Overall success was 88.46% and 77.38% at 1 year and 3 years respectively. Eleven eyes underwent additional IOP lowering procedure and six eyes had undergone explanations of AADI implantation.

Conclusions:

This low-cost non-valved glaucoma drainage implant is effective in reducing IOP and AGM with a safety profile similar to other most widely used non -valved implant in refractory glaucoma.

Financial Disclosure:

None